What question did this study set out to answer?

To assess the clinical outcomes and prognostic significance of immune-related adverse events in patients with metastatic non-squamous NSCLC treated with pembrolizumab and chemotherapy.

May 9, 2026Current OncologyOpen Access

Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab–Chemotherapy: A Real-World Study from Serbia

View Full Paper

Ask AI

Bookmark

Authors

ZBZlatan BojićUniverzitetski Klinički Centar Srbije FMFilip MarkovićUniverzitetski Klinički Centar Srbije MKMilica KontićUniversity of Belgrade

Discussion

Member takes

Implication

Retrospective study evaluates clinical outcomes and immune-related adverse events in metastatic NSCLC, suggesting implications for treatment monitoring.

Key Points

To assess the clinical outcomes and prognostic significance of immune-related adverse events in patients with metastatic non-squamous NSCLC treated with pembrolizumab and chemotherapy.
Conducted a retrospective, single-center study.
Included 107 patients with metastatic non-squamous NSCLC and PD-L1 TPS of 1–49% treated between June 2024 and May 2025.
Utilized Kaplan–Meier and Cox proportional hazards models for analysis.
Median progression-free survival (PFS) was 7.03 months (95% CI, 4.81–9.26).
Immune-related adverse events occurred in 48.6% of patients, mainly thyroid (21.5%) and skin (13.1%) irAEs.
Thyroid (HR 0.36) and skin irAEs (HR 0.28) were associated with prolonged PFS, while ECOG performance status 2 was linked to inferior PFS (HR 3.09, p < 0.001).

Cite This Study

Bojić et al. (2026) studied this question.

synapsesocial.com/papers/69fed090b9154b0b82877ae1 https://doi.org/10.3390/curroncol33050267

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study evaluates clinical outcomes and immune-related adverse events in metastatic NSCLC, suggesting implications for treatment monitoring.

Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab–Chemotherapy: A Real-World Study from Serbia

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab–Chemotherapy: A Real-World Study from Serbia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider